Taiwan Leads Biotech Innovation Showcase at BioJapan 2025

Taiwan is poised to make a significant impact at BioJapan 2025, taking place in Yokohama from October 8 to October 10, 2025. The Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) will lead a delegation of 16 biotech industry partners, showcasing the potential of Taiwan’s thriving biotech ecosystem. This participation aims to foster collaboration between Taiwan and Japan in the fields of biotechnology and innovation.

BPIPO will highlight Taiwan’s strengths in high-growth sectors, particularly in regenerative medicine, artificial intelligence healthcare, precision health, and contract development and manufacturing (CDMOs). The Taiwan Pavilion will serve as a platform for Taiwanese companies to present their innovative capabilities and explore partnerships with Japanese firms.

Taiwan’s biotech landscape has been increasingly influential in Japan. For instance, in 2024, Japan’s CBC became the official distributor for Taiwan’s TBMC, marking a pivotal expansion for Taiwanese businesses in the Japanese market. Additionally, Leeuwenhoek successfully launched its Flora Le Light Synbiotic in Japan, further establishing Taiwan’s presence.

Collaborations between Taiwan and Japan have led to remarkable advancements. AM Biotech recently registered its high-purity targeted exosomes with the Japan Cosmetic Industry Association. These exosomes are now being utilized not only in cosmetics but also in regenerative medicine. Another Taiwanese firm, LumiSTAR, has been selected for Takeda Pharmaceutical’s COCKPI-T® program, which focuses on drug discovery and development.

The delegation’s efforts extend to enhancing manufacturing capabilities. This year, Amaran Biotech entered a strategic partnership with Nippon Fine Chemical to improve CDMO manufacturing technology for nanoparticle-based drugs in both countries. Moreover, Steminent aims to secure certification by 2026 for its innovative regenerative medicine product, Stemchymal®, after recently obtaining Foreign Manufacturer Accreditation from the Japanese government.

As part of the delegation’s activities, Creative Life Science will sign a memorandum of understanding (MOU) with Japan’s Myoridge. This agreement will leverage their combined expertise in cell culture and production, paving the way for new developments in regenerative medicine.

The Taiwan delegation will also engage with Astellas Pharma, one of Japan’s leading pharmaceutical companies, visiting its SakuLab facility to explore collaborative opportunities in cell therapy and bioprocessing.

The roster of participants in this influential delegation reflects the commitment to deepening ties and fostering innovation between Taiwan and Japan. For more information, visit the official BPIPO website at https://ccd.nat.gov.tw/biopharm.

Media inquiries can be directed to Janet Chung at [email protected].